Guggenheim Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-14,790
| Closed | -$112K | – | 1710 |
|
|
2024
Q3 | $112K | Sell |
14,790
-1,065
| -7% | -$8.09K | ﹤0.01% | 1823 |
|
|
2024
Q2 | $98K | Buy |
15,855
+34
| +0.2% | +$210 | ﹤0.01% | 1826 |
|
|
2024
Q1 | $80.4K | Sell |
15,821
-220
| -1% | -$1.12K | ﹤0.01% | 1851 |
|
|
2023
Q4 | $96.1K | Sell |
16,041
-106,281
| -87% | -$637K | ﹤0.01% | 1851 |
|
|
2023
Q3 | $866K | Buy |
122,322
+8,766
| +8% | +$62.1K | 0.01% | 1164 |
|
|
2023
Q2 | $799K | Sell |
113,556
-15,009
| -12% | -$106K | 0.01% | 1273 |
|
|
2023
Q1 | $1.07M | Sell |
128,565
-9,759
| -7% | -$81.4K | 0.01% | 1144 |
|
|
2022
Q4 | $1.59M | Buy |
138,324
+33,325
| +32% | +$383K | 0.01% | 941 |
|
|
2022
Q3 | $1.32M | Sell |
104,999
-24,724
| -19% | -$312K | 0.01% | 1008 |
|
|
2022
Q2 | $1.37M | Buy |
129,723
+17,693
| +16% | +$187K | 0.01% | 1074 |
|
|
2022
Q1 | $1.82M | Sell |
112,030
-13,065
| -10% | -$213K | 0.01% | 1066 |
|
|
2021
Q4 | $1.73M | Buy |
125,095
+111,531
| +822% | +$1.54M | 0.01% | 1122 |
|
|
2021
Q3 | $195K | Buy |
+13,564
| New | +$195K | ﹤0.01% | 2070 |
|
|
2015
Q1 | – | Sell |
-264,963
| Closed | -$3.22M | – | 3031 |
|
|
2014
Q4 | $3.22M | Buy |
264,963
+36,223
| +16% | +$440K | 0.01% | 1380 |
|
|
2014
Q3 | $2.24M | Buy |
228,740
+202,149
| +760% | +$1.98M | 0.01% | 1661 |
|
|
2014
Q2 | $339K | Buy |
26,591
+2,672
| +11% | +$34.1K | ﹤0.01% | 2684 |
|
|
2014
Q1 | $253K | Buy |
23,919
+6,309
| +36% | +$66.7K | ﹤0.01% | 2748 |
|
|
2013
Q4 | $134K | Buy |
17,610
+1,045
| +6% | +$7.95K | ﹤0.01% | 2862 |
|
|
2013
Q3 | $121K | Sell |
16,565
-3,467
| -17% | -$25.3K | ﹤0.01% | 2771 |
|
|
2013
Q2 | $31K | Buy |
+20,032
| New | +$31K | ﹤0.01% | 2863 |
|